Free Trial

Evommune, Inc. (NYSE:EVMN) Stock Has Consensus Price Target of $30.50 According to Analysts

Evommune logo with Healthcare background
Image from MarketBeat Media, LLC.

Evommune, Inc. (NYSE:EVMN - Get Free Report) has received a consensus rating of "Moderate Buy" from the sixteen analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, ten have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $30.50.

EVMN has been the subject of several recent analyst reports. Raymond James Financial set a $18.00 target price on shares of Evommune in a report on Wednesday, September 9th. Weiss Ratings lowered shares of Evommune from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, September 11th. Cantor Fitzgerald restated an "overweight" rating on shares of Evommune in a report on Friday, September 18th. Morgan Stanley started coverage on shares of Evommune in a research report on Tuesday, October 20th. They issued an "overweight" rating and a $26.00 price target for the company. Finally, Needham & Company LLC decreased their price objective on shares of Evommune from $28.00 to $25.00 and set a "buy" rating for the company in a research note on Friday.

Check Out Our Latest Report on Evommune

Institutional Trading of Evommune

A number of hedge funds have recently modified their holdings of EVMN. Janus Henderson Group PLC acquired a new stake in shares of Evommune in the first quarter worth $20,615,000. Defilade Capital Management L.P. raised its position in Evommune by 215.0% during the first quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company's stock valued at $15,601,000 after buying an additional 463,171 shares during the period. Perceptive Advisors LLC acquired a new position in Evommune during the first quarter valued at $10,308,000. Velan Capital Investment Management LP lifted its stake in Evommune by 1.1% in the 2nd quarter. Velan Capital Investment Management LP now owns 451,255 shares of the company's stock worth $5,997,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Stempoint Capital LP lifted its stake in Evommune by 184.1% in the 1st quarter. Stempoint Capital LP now owns 193,777 shares of the company's stock worth $4,385,000 after acquiring an additional 125,581 shares in the last quarter.

Evommune Stock Up 0.2%

NYSE:EVMN opened at $7.65 on Monday. Evommune has a 1-year low of $4.94 and a 1-year high of $33.20. The firm has a market capitalization of $316.29 million and a price-to-earnings ratio of -2.01. The stock has a fifty day simple moving average of $7.56 and a 200 day simple moving average of $17.11.

Evommune (NYSE:EVMN - Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.03). Equities analysts predict that Evommune will post -3.35 earnings per share for the current year.

About Evommune

(Get Free Report)

Evommune is a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. Founded in 2020, the company focuses on biological pathways involved in inflammation and aims to develop treatments for conditions with significant unmet medical needs. Its pipeline includes EVO756, an oral investigational medicine designed to block MRGPRX2, a receptor involved in mast-cell activation. The candidate is being studied for inflammatory skin disorders, including chronic spontaneous urticaria and atopic dermatitis.

Further Reading

Analyst Recommendations for Evommune (NYSE:EVMN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Evommune Right Now?

Before you consider Evommune, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evommune wasn't on the list.

While Evommune currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines